Patents Assigned to Genentech
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20090186363
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 11, 2009
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20090186018
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: September 28, 2006
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Alex Abbas, Sarah C. Bodary-Winter, Hilary Clark, Jill R. Schoenfeld, William I. Wood, Thomas D. Wu
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20090186409
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 29, 2007
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi S. Philips, Paul Polakis, Victoria Smith, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Heregulin variants
    Patent number: 7563583
    Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-?1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: July 21, 2009
    Assignee: Genentech, Inc.
    Inventors: Marcus D Ballinger, Jennifer T Jones, Wayne J Fairbrother, Mark S Sliwkowski, James A Wells
  • PRO4356 polypeptides
    Patent number: 7563867
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: July 21, 2009
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Jian Chen, Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Victoria Smith, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • PLEXIND1 AGONISTS AND THEIR USE
    Publication number: 20090181035
    Abstract: The present invention relates to PLEXIND1 agonists and their use for the treatment of disorders associated with angiogenesis, including cancer.
    Type: Application
    Filed: January 9, 2009
    Publication date: July 16, 2009
    Applicant: Genentech, Inc.
    Inventors: Ryan J. Watts, Alexander W. Koch, Marc Tessier-Lavigne
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20090181014
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 16, 2009
    Applicant: Genentech, Inc.
    Inventors: Heidi S. Phillips, Yu-Ju G. Meng, Richard L. Vandlen
  • NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20090181024
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 16, 2009
    Applicant: Genentech, Inc.
    Inventors: Daryl T. Baldwin, Sarah C. Bodary, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
  • HUMANIZED ANTI-CD40 ANTIBODIES AND THEIR METHODS OF USE
    Publication number: 20090181015
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: May 26, 2006
    Publication date: July 16, 2009
    Applicants: SEATTLE GENETICS, INC., GENENTECH, INC.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
  • HER2 antibody composition
    Patent number: 7560111
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: July 14, 2009
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Martin Vanderlaan
  • CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
    Publication number: 20090175865
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: March 6, 2009
    Publication date: July 9, 2009
    Applicant: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • PYRROLIDINE INHIBITORS OF IAP
    Publication number: 20090176822
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4?, R5, R6 and R6? are as described herein.
    Type: Application
    Filed: April 17, 2008
    Publication date: July 9, 2009
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Vickie Hsiao-Wei Tsui, Cuong Ly, John A. Flygare
  • Methods of using death receptor ligands and CD20 antibodies
    Publication number: 20090175854
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies.
    Type: Application
    Filed: September 7, 2005
    Publication date: July 9, 2009
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Anti-PRO335 antibodies
    Patent number: 7557192
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: July 7, 2009
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Giang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Jennie P. Mather, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS
    Publication number: 20090169556
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: March 10, 2009
    Publication date: July 2, 2009
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin Kim
  • THERAPY OF RITUXIMAB-REFRACTORY RHEUMATOID ARTHRITIS PATIENTS
    Publication number: 20090169550
    Abstract: A method is disclosed of treating a rituximab-refractory rheumatoid arthritis (RA) patient comprising administering an anti-CD20 antibody other than rituximab to the patient in an amount effective to treat the RA.
    Type: Application
    Filed: December 19, 2008
    Publication date: July 2, 2009
    Applicant: Genentech, Inc.
    Inventor: WOLFGANG DUMMER
  • APO-2L receptor agonist and CPT-11 synergism
    Publication number: 20090169569
    Abstract: Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.
    Type: Application
    Filed: September 12, 2008
    Publication date: July 2, 2009
    Applicant: Genentech, Inc.
    Inventors: Enrique Escandon, Sean K. Kelley, Hong Xiang, Judith A. Fox
  • Apo-2 ligand
    Publication number: 20090162364
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 28, 2006
    Publication date: June 25, 2009
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Human growth hormone aqueous formulation
    Publication number: 20090163419
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Application
    Filed: January 15, 2009
    Publication date: June 25, 2009
    Applicant: Genentech, Inc.
    Inventors: Barbara H. O'Connor, James Q. Oeswein
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20090155257
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 18, 2009
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, ANDREW C. CHAN, CRAIG W. CROWLEY, HENRY B. LOWMAN, GERALD R. NAKAMURA, LEONARD G. PRESTA